Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sameer Patel

Plastic and Reconstructive Surgery Philadelphia, PA Medical Doctor

NPI 1912060344 CMS profile 268323

333 Cottman Ave, Philadelphia, PA 19111

Open in the dashboard

General payments

$16,385

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sameer Patel of Philadelphia, PA is reported in the CMS Open Payments database as having received $16,385 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,677 28
2024 General $2,399 14
2023 General $4,735 25
2022 General $2,615 17
2021 General $129 3
2020 General $53 3
2019 General $778 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sameer Patel
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Sameer Patel were reported at $5,677. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Sameer Patel Plastic and Reconstructive Surgery median Middle half National median
2019 $778 $335 $121–$1,264 $163
2020 $53 $162 $57–$417 $114
2021 $129 $245 $89–$735 $132
2022 $2,615 $325 $120–$932 $149
2023 $4,735 $343 $129–$999 $160
2024 $2,399 $390 $141–$1,085 $164
2025 $5,677 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Integra LifeSciences Corporation $3,845 11 payments
  2. KLS-Martin L.P. $3,000 1 payment
  3. TELA Bio, Inc. $2,716 26 payments
  4. RTI Surgical, Inc $2,012 7 payments
  5. AxoGen $1,725 8 payments
  6. Davol Inc. $450 1 payment
  7. Mentor Worldwide LLC $371 6 payments
  8. Innovation Technologies Inc $352 4 payments
  9. Smith+Nephew, Inc. $312 4 payments
  10. AbbVie, Inc. $288 2 payments
  11. Other $1,313 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,075 4 payments
  2. Food and Beverage $5,805 94 payments
  3. Honoraria $3,000 1 payment
  4. Travel and Lodging $1,055 3 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $450 1 payment
Products named General payments · program years 2019–2025
  1. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $2,436 22 payments
  2. CORTIVA ALLOGRAFT DERMIS $2,012 7 payments
  3. DuraSorb Monofilament Mesh $1,950 1 payment
  4. SURGIMEND $1,741 6 payments
  5. CODMAN CERTAS $1,625 1 payment
  6. AXOGUARD HA+ NERVE PROTECTOR $1,480 5 payments
  7. AXOGUARD Neurology $1,480 5 payments
  8. AXOGUARD NERVE CAP $1,480 5 payments
  9. AXOGUARD Neurology $1,480 5 payments
  10. Irrisept $352 4 payments
  11. Other $4,906 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$62,617

Medicare's payments for the services billed

Medicare patients

84

Average age 69

Services billed

182

59 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Cancer 70%
Arthritis 51%
Ischemic heart disease 33%
Diabetes 31%
Chronic kidney disease 31%
Depression 30%
Osteoporosis 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record